Last Updated:
13 Aug 2025, 03:46:40 PM (IST)
Ind-Swift Limited
NSE: INDSWFTLTD BSE: INDSWFTLTD
NSE
15.76
0.91 (6.13%)
Prev Close
14.85
Open Price
15.16
Volume
645,158
Today Low / High
15.15 / 17.82
52 WK Low / High
12 / 34.7
Range
15 - 17
BSE
15.70
0.72 (4.81%)
Prev Close
14.98
Open Price
14.86
Volume
97,760
Today Low / High
14.86 / 17.82
52 WK Low / High
12 / 34.49
Range
15 - 16
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 15.76 (target range: 15 - 17), reflecting a change of 0.91 (6.12795%). On the BSE, it is listed at 15.7 (target range: 15 - 16), showing a change of 0.72 (4.80641%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Ind-Swift Limited Graph
Ind-Swift Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Ind-Swift Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 15.76, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 15.70 | 15.86 | 14.27 - 17.44 |
| 16.01 | 12.81 - 19.22 | ||
| 16.17 | 11.32 - 21.02 | ||
| Bearish Scenario | 15.70 | 15.54 | 13.99 - 17.10 |
| 15.39 | 12.31 - 18.46 | ||
| 15.23 | 10.66 - 19.80 |
Overview of Ind-Swift Limited
ISIN
INE788B01028
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
187,242
Market Cap
853,635,672
Last Dividend
0
Official Website
IPO Date
2004-10-18
DCF Diff
32.60
DCF
-14
Financial Ratios Every Investor Needs
Stock Dividend of INDSWFTLTD
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2011-09-21 | September 21, 11 | 0.4 | 0.4 | 2011-09-22 | 2011-10-26 | 2011-09-02 |
| 2010-09-24 | September 24, 10 | 0.4 | 0.4 | 2010-09-27 | 2010-10-30 | 2010-09-07 |
| 2009-09-17 | September 17, 09 | 0.4 | 0.4 | 2009-09-19 | 2009-10-24 | 2009-08-21 |
| 2008-09-19 | September 19, 08 | 0.4 | 0.4 | 2008-09-23 | 2008-11-01 | 2008-08-25 |
| 2007-09-21 | September 21, 07 | 0.4 | 0.4 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 515.23 Cr | 260.18 Cr | 255.05 Cr | 0.4950 | 0.00 Cr | 0.00 Cr | -0.52 Cr | 283.45 Cr | 52.33 | 350.57 Cr | 0.5501 |
| 2024-03-31 | 502.47 Cr | 285.22 Cr | 217.25 Cr | 0.4324 | 9.79 Cr | 78.61 Cr | 32.17 Cr | 14.23 Cr | 2.63 | 104.94 Cr | 0.0283 |
| 2023-03-31 | 398.89 Cr | 241.89 Cr | 157.00 Cr | 0.3936 | 9.59 Cr | 16.97 Cr | 16.19 Cr | 26.04 Cr | 4.81 | 114.47 Cr | 0.0653 |
| 2022-03-31 | 391.30 Cr | 236.11 Cr | 155.19 Cr | 0.3966 | 5.24 Cr | 12.29 Cr | 31.06 Cr | -20.02 Cr | -3.70 | 68.40 Cr | -0.0512 |
| 2021-03-31 | 352.16 Cr | 209.77 Cr | 142.40 Cr | 0.4043 | 3.90 Cr | 10.34 Cr | 18.03 Cr | -29.82 Cr | -5.50 | 54.66 Cr | -0.0847 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 69.51 Cr | 727.95 Cr | 1,130.28 Cr | -402.3280 Cr | 873.75 Cr | 804.24 Cr | 107.25 Cr | 231.99 Cr | 0.00 Cr | 0.00 Cr | 80.76 Cr | 280.9118 Cr |
| 2024-03-31 | 63.14 Cr | 654.47 Cr | 1,345.30 Cr | -690.8252 Cr | 1,014.00 Cr | 950.86 Cr | 64.09 Cr | 224.77 Cr | 0.00 Cr | 0.00 Cr | 1.26 Cr | 320.3669 Cr |
| 2023-03-31 | 13.33 Cr | 649.21 Cr | 1,353.91 Cr | -704.6988 Cr | 992.62 Cr | 979.29 Cr | 89.35 Cr | 234.27 Cr | 51.77 Cr | 0.00 Cr | 1.26 Cr | 936.3304 Cr |
| 2022-03-31 | 16.18 Cr | 631.76 Cr | 1,352.08 Cr | -720.3211 Cr | 1,021.67 Cr | 1,018.81 Cr | 69.58 Cr | 234.12 Cr | 35.02 Cr | 0.00 Cr | 1.28 Cr | 717.5901 Cr |
| 2021-03-31 | 28.99 Cr | 671.57 Cr | 1,366.74 Cr | -695.1644 Cr | 1,008.54 Cr | 985.50 Cr | 62.85 Cr | 245.14 Cr | 13.41 Cr | 0.00 Cr | 1.86 Cr | 706.1600 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 15.8560 Cr | 3.2279 Cr | -12.7105 Cr | -24.8652 Cr | 6.3734 Cr | 69.5102 Cr | -40.7212 Cr | 7.9418 Cr | 25.8633 Cr | 0.0000 Cr | -43.1578 Cr |
| 2024-03-31 | 15.2828 Cr | 76.6072 Cr | -42.0810 Cr | -13.2103 Cr | 49.8090 Cr | 63.1368 Cr | -28.4931 Cr | 14.2313 Cr | 21.3798 Cr | 0.0000 Cr | 25.2567 Cr |
| 2023-03-31 | 73.0459 Cr | -29.3450 Cr | -46.5556 Cr | 42.2161 Cr | -2.8547 Cr | 13.3278 Cr | -30.8298 Cr | -34.5420 Cr | 17.5392 Cr | 0.0000 Cr | -19.7655 Cr |
| 2022-03-31 | 50.2021 Cr | -18.4163 Cr | -44.5950 Cr | 30.6257 Cr | -12.8092 Cr | 16.1825 Cr | -19.5764 Cr | -20.3364 Cr | -24.1380 Cr | 0.0000 Cr | -6.7366 Cr |
| 2021-03-31 | 83.1928 Cr | -16.7126 Cr | -54.2471 Cr | 62.9770 Cr | 12.2331 Cr | 28.9917 Cr | -20.2158 Cr | -29.8160 Cr | -0.0467 Cr | 0.0000 Cr | -10.4409 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 144.90 Cr | 71.14 Cr | 73.77 Cr | 0.5091 | -9.15 Cr | 256.60 Cr | 47.37 | 278.40 Cr | 1.7708 |
| 2024-12-31 | 120.13 Cr | 55.45 Cr | 64.68 Cr | 0.5384 | 1.77 Cr | -5.50 Cr | -1.02 | 9.98 Cr | -0.0458 |
| 2024-09-30 | 136.35 Cr | 69.89 Cr | 66.46 Cr | 0.4874 | 9.01 Cr | 4.11 Cr | 0.76 | 19.03 Cr | 0.0302 |
| 2024-06-30 | 113.85 Cr | 63.71 Cr | 50.15 Cr | 0.4404 | 30.21 Cr | 28.24 Cr | 5.21 | 43.15 Cr | 0.2480 |
| 2024-03-31 | 135.23 Cr | 99.32 Cr | 35.91 Cr | 0.2656 | 7.61 Cr | 37.54 Cr | 6.93 | 61.08 Cr | 0.2776 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 69.51 Cr | 11.31 Cr | 80.82 Cr | 158.68 Cr | 107.25 Cr | 399.83 Cr | 231.99 Cr | 727.95 Cr | 1,130.28 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 68.85 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 658.47 Cr |
| 2024-09-30 | 68.85 Cr | 0.00 Cr | 68.85 Cr | 161.62 Cr | 88.46 Cr | 383.81 Cr | 212.43 Cr | 685.57 Cr | 1,344.04 Cr |
| 2024-06-30 | 63.14 Cr | 0.00 Cr | 63.14 Cr | 0.00 Cr | 0.00 Cr | 63.14 Cr | 0.00 Cr | 0.00 Cr | 690.83 Cr |
| 2024-03-31 | 63.14 Cr | 0.00 Cr | 63.14 Cr | 152.14 Cr | 64.09 Cr | 341.79 Cr | 224.77 Cr | 654.47 Cr | 1,345.30 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 256.60 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | -5.50 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 4.11 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 28.24 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 37.54 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2005-04-29 | April 29, 05 | 5:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
Chief Executive Officer, MD & Whole Time Director
Gopal Munjal
Gender: Not Specified
Year Born: 1958
Joint MD & Whole Time Director
Vikrant Rai Mehta
Gender: Not Specified
Year Born: 1958
Chief Operating Officer
Anil Agrawal
Gender: male
Year Born:
Chief Financial Officer & GM of Finance & Accounts
Arun K. Seth
Gender: male
Year Born:
Vice President of Human Resources
Om Prakash Thapliyal
Gender: male
Year Born:
Associate Vice President of Quality
Suchitra Bhatnagar
Gender: female
Year Born:
Associate Vice President of Marketing
Rajinder Kumar Gupta
Gender: male
Year Born:
Executive Chairman
Sanjeev Rai Mehta
Gender: male
Year Born: 1956
Senior General Manager of Purchase
Sudhir Sethi
Gender: male
Year Born:
Head of Administration
Annie Mehta
Gender: female
Year Born:
FAQs about Ind-Swift Limited
Who is the CEO of the company?
The CEO is Gopal Munjal.
What is the current market price of the stock?
The current price is ₹15.76.
What is the 52-week price range?
The range is ₹12-34.7.
What is the market capitalization of the company?
The market capitalization is ₹85.36 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 0.33.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Ind-Swift Limited (ISIN: INE788B01028) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹85.36 crores and an average daily volume of 187,242 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.